Waylis Therapeutics

Waylis Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for metabolic disorders, with a primary emphasis on obesity. The company's lead candidate, WLS-101, is a gastric-retentive, controlled-release oral formulation of the GLP-1 receptor agonist exenatide. By utilizing a unique delivery system, Waylis aims to provide a more convenient and tolerable alternative to injectable GLP-1 therapies. The company was founded by experienced industry leaders with a track record in metabolic drug development, including former executives from Altimmune. Waylis is currently advancing its clinical programs to address the significant unmet need in the global obesity market.